Skip to main content
SpringerLink
Log in

Impact of the Fluoroquinolones on Gastrointestinal Flora

  • State-of-The-Art Presentations
  • Published:
Drugs Aims and scope Submit manuscript

Summary

A number of studies have been performed to evaluate the effect of the fluoroquinolones on gastrointestinal flora. The fluoroquinolones have only slight or no effect on the oropharyngeal flora, except when Neisseria, Haemophilus or Branhamella spp. are present. Studies have consistently shown that Gram-negative facultative bacteria of the lower intestinal flora are strongly suppressed during administration of these agents. Total faecal anaerobes are generally unchanged. The effect of the fluoroquinolones on Gram-positive bacteria is more variable with mild to moderate suppression reported with some agents. In view of the high faecal concentrations of the fluoroquinolones, the general lack of effect on anaerobes is surprising; it may be attributable to the large number of microorganisms found in faeces and faecal binding of the fluoroquinolones. Several recent studies suggest that the effects of some fluoroquinolones on faecal anaerobes and Gram-positive cocci may be more profound in certain patient populations such as bone marrow transplant recipients and patients undergoing gastrointestinal surgery. Colonisation with yeasts and the emergence of resistant bacterial strains have been reported during or after fluoroquinolone administration in some studies. Future studies will need to investigate the effect of the newer agents with greater activity against anaerobes and Gram-positive cocci on the gastrointestinal flora and to continue surveillance for resistant organisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Appelbaum PC, Spangler SK, Jacobs MR. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents. Antimicrobial Agents and Chemotherapy 35: 1214–1218, 1991

    Article  PubMed  CAS  Google Scholar 

  • Appelbaum PC, Spangler SK, Strauss M. Reduction of oral flora with ciprofloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 21: 243–249, 1988

    Article  PubMed  CAS  Google Scholar 

  • Arcieri G, Griffith E, Gruenwaldt G, Heyd A, O’Brien B, et al. Ciprofloxacin: an update of clinical experience. American Journal of Medicine 82 (Suppl. 4A): 381–386, 1987

    PubMed  CAS  Google Scholar 

  • Barry AL, Fuchs PC. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrobial Agents and Chemotherapy 35: 955–960, 1991

    Article  PubMed  CAS  Google Scholar 

  • Bergan T. Pharmacokinetics of fluorinated quinolones. In Andriole VT (Ed.) The quinolones, pp. 119–154, Academic Press, London, 1988

    Google Scholar 

  • Bergan T, Delin C, Johansen S, Kolstad IM, Nord CE, et al. Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and faecal microflora. Antimicrobial Agents and Chemotherapy 29: 298–302, 1986

    Article  PubMed  CAS  Google Scholar 

  • Boerema JB, Olthof BJ, vanSaene HK. Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections. Scandinavian Journal of Infectious Diseases 48 (Suppl.): 27–31, 1986

    PubMed  CAS  Google Scholar 

  • Brismar B, Edlund C, Malmborg AS, Nord CE. Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. Antimicrobial Agents and Chemotherapy 34: 481–483, 1990

    Article  PubMed  CAS  Google Scholar 

  • Brook I. Inoculum effect. Reviews of Infectious Diseases 11: 361–368, 1989

    Article  PubMed  CAS  Google Scholar 

  • Brumfitt W, Franklin I, Grady D, Hamilton-Miller JMT, Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrobial Agents and Chemotherapy 26: 757–761, 1984

    Article  PubMed  CAS  Google Scholar 

  • Chin NX, Gu JW, Yu KW, Zhang YX, Neu HC. In vitro activity of sparfloxacin. Antimicrobial Agents and Chemotherapy 35: 567–571, 1991

    Article  PubMed  CAS  Google Scholar 

  • Cofsky RD, du Bouhet L, Landesman SH. Recovery of norfloxacin in feces after administration of a single oral dose to human volunteers. Antimicrobial Agents and Chemotherapy 26: 110–111, 1984

    Article  PubMed  CAS  Google Scholar 

  • Daikos GL, Kathpalia SB, Sharifi R, Lolans VT, Jackson GG. Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. American Journal of Medicine 82 (Suppl. 4A): 290–294, 1987

    PubMed  CAS  Google Scholar 

  • de Vries-Hospers HG, Welling GW, van der Waaij D. Norfloxacin for selective decontamination. A study in human volunteers. Progress in Clinical and Biological Research 181: 259–262, 1985

    Google Scholar 

  • de Vries-Hospers HG, Welling GW, van der Waaij D. Influence of quinolones on throat- and faecal flora of healthy volunteers. Pharmaceutisch Weekblad Scientific Edition 9 (Suppl.): 41–44, 1987

    Article  Google Scholar 

  • Du Pont H. Use of quinolones in the treatment of gastrointestinal infections. European Journal of Clinical Microbiology and Infectious Diseases 10: 325–329, 1991

    Article  Google Scholar 

  • Edlund C, Bergan T, Josefsson K, Solberg R, Nord CE. Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. Scandinavian Journal of Infectious Diseases 19: 113–121, 1987a

    Article  PubMed  CAS  Google Scholar 

  • Edlund C, Brismar B, Nord CE. Effect of lomefloxacin on the normal oral and intestinal microflora. European Journal of Clinical Microbiology and Infectious Diseases 9: 35–39, 1990

    Article  CAS  Google Scholar 

  • Edlund C, Kager L, Malmborg AS, Sjostedt S, Nord CE. Effect of ofloxacin on oral and gastrointestinal microflora in patients undergoing gastric surgery. European Journal of Clinical Microbiology and Infectious Diseases 7: 135–145, 1988a

    Article  CAS  Google Scholar 

  • Edlund C, Lidbeck A, Kager L, Nord CE. Effect of enoxacin on colonic microflora of healthy volunteers. European Journal of Clinical Microbiology and Infectious Diseases 6: 298–300, 1987b

    Article  CAS  Google Scholar 

  • Edlund C, Lindqvist L, Nord CE. Norfloxacin binds to human fecal material. Antimicrobial Agents and Chemotherapy 32: 1869–1874, 1988b

    Article  PubMed  CAS  Google Scholar 

  • Edlund C, Nord CE. Manipulation of the oropharyngeal and intestinal microflora by norfloxacin: microbiological and clinical aspects. Scandinavian Journal of Infectious Diseases 56 (Suppl.): 14–21, 1988a

    PubMed  CAS  Google Scholar 

  • Edlund C, Nord CE. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora. Infection 16: 8–12, 1988b

    Article  PubMed  CAS  Google Scholar 

  • Edlund C, Nord CE. Suppression of the oropharyngeal and gastrointestinal microflora by ciprofloxacin: microbiological and clinical consequences. Scandinavian Journal of Infectious Diseases 60 (Suppl.): 98–103, 1989

    PubMed  CAS  Google Scholar 

  • Ehrenpreis ED, Lievens MW, Craig RM. Clostridium difficile-associated diarrhea after norfloxacin. Journal of Clinical Gastroenterology 12: 188–189, 1990

    Article  PubMed  CAS  Google Scholar 

  • Enzensberger R, Shah PM, Knothe H. Impact of oral ciprofloxacin on the faecal flora of healthy volunteers. Infection 13: 273–275, 1985

    Article  PubMed  CAS  Google Scholar 

  • Esposito S, Barba D, Galante D, Gaeta GB, Laghezza O. Intestinal microflora changes induced by ciprofloxacin and treatment of portal-systemic encephalopathy (PSE). Drugs Under Experimental and Clinical Research 13: 641–646, 1987

    PubMed  CAS  Google Scholar 

  • Fuchs PC, Barry AL, Jones RN, Thornsberry C, Ayers LW, et al. CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria. Diagnostic Microbiology and Infectious Disease 6: 185–192, 1987

    Article  PubMed  CAS  Google Scholar 

  • Fujimaki K, Noumi T, Saikawa I, Inoue M, Mitsuhashi S. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrobial Agents and Chemotherapy 32: 827–833, 1988

    Article  PubMed  CAS  Google Scholar 

  • Furet YX, Pechere JC. Newly documented antimicrobial activity of quinolones. European Journal of Clinical Microbiology and Infectious Diseases 10: 249–254, 1991

    Article  CAS  Google Scholar 

  • Gines P, Rimola A, Planas R, Vargas V, Marco F, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 12: 716–724, 1990

    Article  PubMed  CAS  Google Scholar 

  • Giuliano M, Pantosti A, Gentile G, Venditti M, Arcese W, et al. Effects on oral and intestinal microfloras of norfloxacin and pefloxacin for selective decontamination in bone marrow transplant patients. Antimicrobial Agents and Chemotherapy 33: 1709–1713, 1989

    Article  PubMed  CAS  Google Scholar 

  • Goldstein EJ, Citron DM, Corrado ML. Effect of inoculum size on in vitro activity of norfloxacin against fecal anaerobic bacteria. Rationale for selective decontamination of the digestive tract. American Journal of Medicine 82 (Suppl. 6B): 84–87, 1987

    Article  PubMed  CAS  Google Scholar 

  • Goossens H, De Mol P, Coignau H, Levy J, Grados O, et al. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens. Antimicrobial Agents and Chemotherapy 27: 388–392, 1985

    Article  PubMed  CAS  Google Scholar 

  • Holt HA, Lewis DA, White LO, Bastable SY, Reeves DS. Effect of oral ciprofloxacin on the faecal flora of healthy volunteers. European Journal of Clinical Microbiology 5: 201–205, 1986

    Article  PubMed  CAS  Google Scholar 

  • Janin N, Meugnier H, Desnottes JF, Woehrle R, Fleurette J. Recovery of pefloxacin in saliva and feces and its action on oral and fecal floras of healthy volunteers. Antimicrobial Agents and Chemotherapy 31: 1665–1668, 1987

    Article  PubMed  CAS  Google Scholar 

  • Karp JE, Merz WG, Hendricksen C, Laughton B, Redden T, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Annals of Internal Medicine 106: 1–6, 1987

    PubMed  CAS  Google Scholar 

  • Kern W, Kurrle E, Vanek E. Ofloxacin for prevention of bacterial infections in granulocytopenic patients. Infection 15: 427–433, 1987

    Article  PubMed  CAS  Google Scholar 

  • King A, Bethune L, Phillips I. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin. Journal of Antimicrobial Chemotherapy 28: 719–725, 1991

    Article  PubMed  CAS  Google Scholar 

  • Klastersky J. Chemoprophylaxis of gram-negative infections in neutropenic patients. European Urology 17 (Suppl. 1): 40–45, 1990

    PubMed  Google Scholar 

  • Lang R, Lishner M, Segev S, Rubinstein E. Ofloxacin and the gastrointestinal tract: a potential role in the treatment of bacterial enteritis. Journal of Antimicrobial Chemotherapy 26 (Suppl. D): 45–53, 1990

    PubMed  Google Scholar 

  • Leigh DA, Harris C, Tait S, Walsh B, Hancock P. Pharmacokinetic study of lomefloxacin and its effect on the faecal flora of volunteers. Journal of Antimicrobial Chemotherapy 27: 655–662, 1991a

    Article  PubMed  CAS  Google Scholar 

  • Leigh DA, Tait S, Walsh B. Antibacterial activity of lomefloxacin. Journal of Antimicrobial Chemotherapy 27: 589–598, 1991b

    Article  PubMed  CAS  Google Scholar 

  • Leigh DA, Walsh B, Harris K, Hancock P, Travers G. Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. Journal of Antimicrobial Chemotherapy 22 (Suppl. C): 115–125, 1988

    PubMed  CAS  Google Scholar 

  • Ljungberg B, Nilsson-Ehle I, Edlund C, Nord CE. Influence of ciprofloxacin on the colonic microflora in young and elderly volunteers: No impact of the altered drug absorption. Scandinavian Journal of Infectious Diseases 22: 205–208, 1990

    Article  PubMed  CAS  Google Scholar 

  • Meunier F. Prevention of infections in neutropenic patients with pefloxacin. Journal of Antimicrobial Chemotherapy 26 (Suppl. B): 69–73, 1990

    PubMed  Google Scholar 

  • Miranda AG, Wanger AR, Singh KV, Murray BE. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrobial Agents and Chemotherapy 36: 1325–1328, 1992

    Article  PubMed  CAS  Google Scholar 

  • Murray BE. Impact of fluoroquinolones on the gastrointestinal flora. Review of Infectious Diseases 11 (Suppl. 5): 1372–1378, 1989a

    Article  Google Scholar 

  • Murray BE. Quinolones and the gastrointestinal tract. European Journal of Clinical Microbiology and Infectious Diseases 8: 1093–1101, 1989b

    Article  CAS  Google Scholar 

  • Nakamura S, Minami A, Nakata K, Kurobe N, Kouno K, et al. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrobial Agents and Chemotherapy 33: 1167–1173, 1989

    Article  PubMed  CAS  Google Scholar 

  • Nakashima M, Kanamaru M, Uematsu T, Takiguchi A, Mizuno A, et al. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers. Journal of Antimicrobial Chemotherapy 22 (Suppl. D): 133–144, 1988

    PubMed  CAS  Google Scholar 

  • Nord CE, Edlund C. Clinical impact of newer quinolones: influence on normal microflora. Journal of Chemotherapy 1: 18–23, 1989

    PubMed  CAS  Google Scholar 

  • O’Hare MD, Felmingham D, Ridgway GL, Grüneberg RN. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens. Drugs Under Experimental and Clinical Research 11: 253–257, 1985

    PubMed  Google Scholar 

  • Paganori R, Herzog CH, Braunsteiner A, Hohl P. Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin. Journal of Antimicrobial Chemotherapy 22 (Suppl. D): 3–17, 1988

    Google Scholar 

  • Pecquet S, Andremont A, Tancrede C. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human faecal flora. Antimicrobial Agents and Chemotherapy 29: 1047–1052, 1986

    Article  PubMed  CAS  Google Scholar 

  • Pecquet S, Andremont A, Tancrede C. Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrobial Agents and Chemotherapy 31: 124–125, 1987

    Article  PubMed  CAS  Google Scholar 

  • Phillips I, King A, Shannon K. In vitro properties of the quinolones. In Andriole VT (Ed.) The quinolones, pp. 83–117, Academic Press, London, 1988

    Google Scholar 

  • Pizzo PA. Considerations for the prevention of infectious complications in patients with cancer. Reviews of Infectious Diseases 11 (Suppl. 7): 1551–1563, 1989

    Article  Google Scholar 

  • Rademaker CM, Hoepelman IM, Wolfhagen MJ, Beumer H, Rozenberg-Arska M, et al. Results of a double-blind placebo-controlled study using ciprofloxacin for prevention of travellers’ diarrhea. European Journal of Clinical Microbiology and Infectious Diseases 8: 690–694, 1989

    Article  CAS  Google Scholar 

  • Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of ciprofloxacin. Chemotherapy 36: 77–84, 1990

    Article  PubMed  CAS  Google Scholar 

  • Rozenberg-Arska M, Dekker AW, Verhoef J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment. The effect on the fecal flora. Journal of Infectious Diseases 152: 104–107, 1985

    CAS  Google Scholar 

  • Sagara H, Tsunoda T, Nitta Y. Effect of sparfloxacin on fecal microflora and its fecal concentration in patients with bacillary dysentery. Kansenshogaku-Zasshi. Journal of the Japanese Association for Infectious Diseases 65: 1136–1143, 1991

    CAS  Google Scholar 

  • Scully BE, Jules K, Chin NX, Neu HC. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. American Journal of Medicine 82 (Suppl. 4A): 336–338, 1987

    PubMed  CAS  Google Scholar 

  • Shah PM, Enzensberger R, Glogau O, Knothe H. Influence of oral ciprofloxacin or ofloxacin on fecal flora of healthy volunteers. American Journal of Medicine 82 (Suppl. 4A): 333–335, 1987

    CAS  Google Scholar 

  • Shah PM, Sammann A, Schafer V, Seczendi M, Knothe H. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers. Journal of Antimicrobial Chemotherapy 22 (Suppl. D): 209–213, 1988

    PubMed  CAS  Google Scholar 

  • Vanhoof R, Hubrechts JM, Roebben E, Nyssen HJ, Nulens E, et al. The comparative activity of pefloxacin, enoxacin, ciprofloxacin and 13 other antimicrobial agents against enteropathogenic microorganisms. Infection 14: 294–298, 1986

    Article  PubMed  CAS  Google Scholar 

  • van Saene HK, Lemmens SE, vanSaene JJ. Gut decontamination by oral ofloxacin and ciprofloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 22 (Suppl. C): 127–134, 1988a

    PubMed  Google Scholar 

  • van Saene JJM, vanSaene HKF, Geitz JN, Tarko-Smit NJP, Lerk CF. Effects of ciprofloxacin on the intestinal flora. Reviews of Infectious Diseases 10 (Suppl. 1): 198, 1988b

    Article  Google Scholar 

  • van Saene JJM, vanSaene HKF, Lerk CF. Inactivation of quinolone by feces. Journal of Infectious Diseases 153: 999–1000, 1986

    Article  PubMed  Google Scholar 

  • Wexler HM, Molitoris E, Finegold SM. In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrobial Agents and Chemotherapy 36: 239–243, 1992

    Article  PubMed  CAS  Google Scholar 

  • Wistrom J, Norrby SR, Burman LG, Lundholm R, Jellheden B, et al. Norfloxacin versus placebo for prophylaxis against travellers’ diarrhoea. Journal of Antimicrobial Chemotherapy 20: 563–574, 1987

    Article  PubMed  CAS  Google Scholar 

  • Wolfson JS, Hooper DC. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and Chemotherapy 28: 581–586, 1985

    Article  PubMed  CAS  Google Scholar 

  • Wolfson JS, Hooper DC. Pharmacokinetics of quinolones: newer aspects. Eurppean Journal of Clinical Microbiology and Infectious Diseases 10: 267–274, 1991

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Infectious Diseases, Marmara University School of Medicine, Istanbul, Turkey

    Volkan Korten

  2. Center for Infectious Diseases and Department of Medicine, University of Texas Medical School at Houston, 6431 Fannin, 1.728 JFB, Houston, Texas, TX 77030, USA

    Volkan Korten &  Barbara E. Murray

Authors
  1. Volkan Korten
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barbara E. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Korten, V., Murray, B.E. Impact of the Fluoroquinolones on Gastrointestinal Flora. Drugs 45 (Suppl 3), 125–133 (1993). https://doi.org/10.2165/00003495-199300453-00021

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199300453-00021

Keywords

Search

Navigation